Symbols

NBIX

Neurocrine Biosciences·NASDAQ

--(--)

NBIX Profile

Neurocrine Biosciences, Inc.

A leading neuroscience-focused biopharmaceutical company that develops pharmaceuticals for neurological, endocrine and psychiatric disorders

Industry

Pharmaceutical

Established Date

Listing Date

05/23/1996

Exchange

NASDAQ Stock Exchange

Full-time Employees

2,000

Fiscal Year Ends

12-31

Website

www.neurocrine.com

Security Type

Common stock

Office address

6027 Edgewood Bend Court, San Diego, CA 92130

Business

Introduction

Neurocrine Biosciences, Inc., was incorporated in California in January 1992 and re-incorporated in Delaware in May 1996. The company is a neuroscience-focused biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for underaddressed neurological, psychiatric, endocrine and immune system diseases. Its product portfolio covers therapies approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia, Huntington's disease-related chorea, classic congenital adrenal hyperplasia, endometriosis and uterine fibroids, and has a diversified pipeline of research in core therapeutic areas from small molecules to gene therapy.